공지사항

Acute Myeloid Leukemia Injuries

Acute myeloid leukemia (AML) occurs in your bone marrow, which is the soft inner part of certain bones where new blood cells are produced. It is usually caused by cells that usually form white blood cells, but it can also start in other types.

These abnormal cells accumulate in your blood and bone marrow, crowding out healthy cells. This can lead to problems like anemia, a lack of healthy white blood cells, and easy bleeding.

Symptoms

White blood cells develop in the bone marrow stem cells. They have three main jobs - fighting infections as well as attacking cancerous tissue and controlling inflammation. The earliest or immature versions of these cells are called blasts. They're the ones that are present in patients suffering from acute myeloid leukemia (AML).

When the blasts in the blood are not normal, they cause a variety symptoms. Anemia (too few healthy red blood cells) can cause fatigue. This can cause weakening, dizziness, a rapid heartbeat, and pale skin.

The majority of the time, the blasts don't form a tumor or other growths that are visible in imaging tests such as Xrays and CT scans. They can spread from the bloodstream to other parts of the human body like the central nervous system or the skin. If they do so it could cause headaches as well as breathing issues and confusion.

acute myeloid leukemia injuries myeloidleukemia can result in a lack of platelets which are responsible for clotting blood to stop bleeding. This can result in excessive bruising, nosebleeds bleeding from the gums, and heavy menstrual bleeding in women. It can also lead to an illness known as petechiae. This is defined by small, scattered, purple spots on the skin.

Diagnosis

To determine if you have leukemia, your doctor will conduct a physical exam and inquire about your symptoms. Then, he or she will conduct blood tests. A complete blood count (CBC) is a blood test that measures the number of white blood cells, platelets and red blood cell in your body. A low level of these blood cells can make it difficult to fight infections and may cause fatigue or shortness of breath.

The CBC also looks for blast cells (immature blood cells) in your bone marrow. The blast cells do not mature into healthy blood cells, and they interfere with the development of normal cells, for example, those that transport oxygen to all parts of the body, and also help clot blood. acute myeloid leukemia cancer myelogenous Leukemia is a type of cancer that begins in the white blood cells that are still immature. It could be one of several kinds, each with a different prognosis.

The most common age group for acute myelogenous lymphoma is adults older than 60 years but it may also be a problem for children and adolescents. It can be caused by an infection with a virus, chemotherapy or Acute Myeloid Leukemia Injuries radiation to treat a different disease, or by certain types of syndromes or inherited disorders. It's more common in men than in women. People who have an underlying blood disorder such as myelodysplastic Sclerosis are more likely to develop this type of leukemia. Other risk factors include smoking and long-term exposure to industrial chemicals, such as benzene.

Treatment

The aim of treatment is to rid of the leukemia cells and ensure that they don't return. Your treatment may include chemotherapy, a bone marrow transplant or other kinds of stem cell therapy, radiation and/or targeted therapy. A palliative approach may be required to alleviate symptoms and adverse effects.

Acute myelogenous Lymphoma (AML) occurs when blood stem cells fail to transform into healthy red blood cells, white blood cells or platelets. These abnormal cells are accumulating in bone marrow and blood. They crowd out healthy cells and inhibit the ability of those cells to fight infection. AML is usually fast-growing and becomes worse if not treated. It can spread to other parts of the body, including the central nervous system (brain and spinal cord) as well as the liver and spleen.

The treatment for AML is based on the type and the severity and whether the leukemia cells have spread. Induction therapy is the primary step. It is a method of using high doses of drugs to kill cancer cells and reduce the chances of the relapse.

Then, you can undergo consolidation therapy, which is a combination of standard chemotherapy with targeted drug treatments or a bone marrow transplant. This can help restore healthy bone marrow as well as blood. It can be used to treat AML that has recurred as well as a follow-up after an organ transplantation.

Prevention

acute myeloid leukemia injuries myeloid leukemia (AML) begins in blood-forming stem cells in the bone marrow. These cells usually become red blood cells, which carry oxygen to tissues throughout the body white blood cells that combat disease and infections or platelets that create blood clots to stop bleeding. But in AML, the stem cells change and do not develop into healthy blood cells. This means that the abnormal blood cells block the normal red blood cells as well as white blood cells. This can lead to anemia which can make you feel weak and fatigued. It could also cause a buildup of fluid around the kidneys and heart, Acute Myeloid Leukemia Injuries which can cause trouble breathing and shortness of breath.

A background of a blood disorder, such as myelodysplastic, or other blood cancers, or genetic disorders, like Down syndrome, are all risk factors for AML. Smoking increases your risk of developing AML and so does previous chemotherapy treatment. Radiation exposure can also increase the risk of AML in older people.

To identify AML, your doctor will review your medical background and perform an examination. They will also conduct blood tests to determine your levels of red blood cells, white blood cells, and platelets. Your doctor may use the human leukocyte-antigen (HLA) test, which is a method to determine if you are a suitable donor should you require a stem-cell transplant. This test compares the proteins that are on the surface of your blood cells with the proteins found on a potential donor's cells.